{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/heart-failure-chronic/prescribing-information/managing-diuretics/","result":{"pageContext":{"chapter":{"id":"faad170c-d1ee-59ad-9847-f7afdda6d9b9","slug":"managing-diuretics","fullItemName":"Managing diuretics","depth":2,"htmlHeader":"<!-- begin field 0d2eba0c-4eb0-44b6-8e9c-35108c308468 --><h2>Managing diuretics</h2><!-- end field 0d2eba0c-4eb0-44b6-8e9c-35108c308468 -->","summary":"","htmlStringContent":"<!-- begin item 85ae6ec6-d85b-4f5d-8019-c37af2a00ef4 --><!-- end item 85ae6ec6-d85b-4f5d-8019-c37af2a00ef4 -->","topic":{"id":"3a35207f-30ea-5eca-bfcf-dff091a73359","topicId":"fdc42e20-2c4b-45ed-9093-6c2d4bde6e4d","topicName":"Heart failure - chronic","slug":"heart-failure-chronic","lastRevised":"Last revised in January 2017","chapters":[{"id":"77c928c1-46d0-58c1-ba79-6015f89bc48a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f0aa9151-9d10-566e-85ec-6ccefed25f20","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c036596d-f29d-5486-822a-b46af76451d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fd5e8a95-3e97-5ec2-98ae-5a10c2373213","slug":"changes","fullItemName":"Changes"},{"id":"4c4375f1-a348-5b99-b895-f04a15c64791","slug":"update","fullItemName":"Update"}]},{"id":"7472c037-35d4-5fd2-bba6-dfd891ade816","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cde936d1-3945-5bc6-8c22-9106d78cf77c","slug":"goals","fullItemName":"Goals"},{"id":"bfa0b8d3-fac0-500e-a762-f719dc619f1b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5d2cf55e-1ae2-5000-9c94-e9c86d26a824","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c8203a8a-fc22-5378-b33b-34ddf818dea5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4b5e4f72-1a3e-531c-be82-a1919603c934","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c206f1b2-7616-587d-b3bf-b65ba5b5adb4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ab1d2b81-1f2b-55e5-abf0-c14e4ae4a78d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"cb83ac3c-e97e-5cab-acca-5abebc7bd6b1","slug":"definition","fullItemName":"Definition"},{"id":"66c995b7-504c-5510-9e77-1a9b27ee7dca","slug":"causes","fullItemName":"Causes"},{"id":"88dbdf7b-53b7-5952-97b9-2312c0a2ce63","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0b16521-d808-5dfd-89dc-64fc6ae7f6ce","slug":"prognosis","fullItemName":"Prognosis"},{"id":"262fb896-526d-594f-8142-98c291781249","slug":"complications","fullItemName":"Complications"}]},{"id":"72804751-fb0c-5a96-85b5-982feb950f16","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8b798e41-3fbe-5027-9365-da41e1c98e93","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"e6498250-f313-5ea2-a1e8-2d0342823c39","slug":"how-to-manage-suspected","fullItemName":"How to manage suspected"},{"id":"74e553b4-7cb8-52a6-a573-8715f63a2ba8","slug":"how-to-assess","fullItemName":"How to assess"},{"id":"53bf7ae0-a1d0-5fae-9d3b-57cbc6f03bb8","slug":"what-else-could-it-be","fullItemName":"What else could it be"}]},{"id":"38c5edc8-6b4a-5e71-bb70-cf0a09389ae0","fullItemName":"Management","slug":"management","subChapters":[{"id":"97a0eca4-a290-588b-a16a-bc95b93cd893","slug":"confirmed-heart-failure-with-reduced-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with reduced ejection fraction"},{"id":"34ff8094-815a-55b7-9edd-49f3ac636471","slug":"confirmed-heart-failure-with-preserved-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with preserved ejection fraction"},{"id":"28fde475-ef24-59d3-9171-a8d59a3fb149","slug":"end-stage-heart-failure","fullItemName":"Scenario: End-stage heart failure"},{"id":"c587255a-a47e-57a1-bc4d-967753c38d11","slug":"information-advice-follow-up-referral","fullItemName":"Scenario: Information and advice, follow-up, and referral"}]},{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8fd96acc-3fa6-528b-9351-49db836228b1","slug":"managing-aiiras","fullItemName":"Managing AIIRAs"},{"id":"06c9d276-e5ea-5a0b-9ff4-343f10034763","slug":"managing-ace-inhibitors","fullItemName":"Managing ACE-inhibitors"},{"id":"df53e9a8-07f8-5d37-94cf-78e99d4c8216","slug":"managing-beta-blockers","fullItemName":"Managing beta-blockers"},{"id":"faad170c-d1ee-59ad-9847-f7afdda6d9b9","slug":"managing-diuretics","fullItemName":"Managing diuretics"},{"id":"a3ea6beb-7ee3-586c-9985-47c20d804195","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"7b9c5d56-39f1-53df-b1f9-2dcc5bbb498a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"df3b6e0c-ca5a-59eb-93e6-4b4370389ed2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7a756ff1-7152-5bdd-92ca-7f9e67351dd9","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f5e1707e-f2a9-54e0-92fa-71beb41e38af","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"691681cc-720f-5242-9fb3-3040860027e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7f39ec24-cb87-5fba-ae6b-6fb2d9538859","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4afe2b30-f837-53a3-88df-7b1913a54081","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d4dace55-ef1c-5675-bdbe-180512d549fa","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"dc2762dc-6062-5007-a27e-47adcce5d9ef","slug":"choice-of-diuretic","fullItemName":"Choice of diuretic","depth":3,"htmlHeader":"<!-- begin field 4af62707-8a9f-49f9-8c98-69e1d46f5d79 --><h3>Choice of diuretic</h3><!-- end field 4af62707-8a9f-49f9-8c98-69e1d46f5d79 -->","summary":"","htmlStringContent":"<!-- begin item 2f1c76ba-542b-41c6-9456-287d19ad378d --><!-- begin field 2a38c466-9b7e-43b1-a3b0-44d27cd13359 --><p>Loop diuretics are preferred for the management of oedema due to heart failure.</p><ul><li>The loop diuretics available in the UK are furosemide (most widely used), bumetanide, and torasemide.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 2a38c466-9b7e-43b1-a3b0-44d27cd13359 --><!-- end item 2f1c76ba-542b-41c6-9456-287d19ad378d -->","subChapters":[]},{"id":"327138d3-2a73-521d-875d-af2946a97ece","slug":"key-drug-interactions","fullItemName":"Key drug interactions","depth":3,"htmlHeader":"<!-- begin field abd0c5d2-7898-41b3-85a2-754935788e50 --><h3>Key drug interactions with loop diuretics</h3><!-- end field abd0c5d2-7898-41b3-85a2-754935788e50 -->","summary":"","htmlStringContent":"<!-- begin item d1f527c0-e417-4066-bcc3-3c548b7fb98f --><!-- begin field ec1c318c-f9d8-474f-976e-0d19d9ea1871 --><p><strong>Important drug interactions of loop diuretics include:</strong></p><ul><li><strong>Antibiotics</strong> — increased risk of ototoxicity with aminoglycosides, or vancomycin. Only use concurrently if compelling reasons. Increased nephrotoxicity with aminoglycosides or cefaloridine. Increased risk of hyponatraemia with trimethoprim. Impaired renal function may develop with high doses of certain cephalosporins.</li><li><strong>Antidepressants </strong>— enhanced hypotensive effect with monoamine oxidase inhibitors (MAOIs). Increased risk of postural hypotension with tricyclic antidepressants (TCAs). Increased risk of hypokalaemia with reboxetine.</li><li><strong>Antidiabetics</strong> — hypoglycaemic effects antagonised by furosemide.</li><li><strong>Antihypertensives</strong> — severe hypotension can occur. Consider diuretic dose reduction or stopping for 3 days before starting or increasing angiotensin-converting enzyme (ACE) inhibitor or angiotensin-II receptor antagonist.</li><li><strong>Methorexate</strong> — effects of furosemide may be reduced by methotrexate and furosemide may reduce renal clearance of methotrexate.</li><li><strong>Antipsychotics</strong> — increased risk of cardiac toxicity due to induced hypokalaemia. Avoid concurrent use with pimozide. Increased risk of ventricular arrhythmias with amisulpride or sertindole. Enhanced hypotensive effect with phenothiazines. When administering risperidone, the risks and benefits should be considered prior to use.</li><li><strong>Antiarrhythmics, cardiac glycosides (for example digoxin), and other drugs that prolong the QT interval </strong>— increased risk of cardiac toxicity due to induced electrolyte disturbances. Monitor electrolyte levels.</li><li><strong>Chelating agents</strong> — sucralfate may decrease the gastrointestinal absorption of furosemide (take the drugs at least 2 hours apart).</li><li><strong>Corticosteroids</strong> — diuretic effect antagonized and increased risk of hypokalaemia.</li><li><strong>Dopaminergics</strong> — enhanced hypotensive effect with levodopa.</li><li><strong>Laxatives</strong> — increases risk of potassium loss.</li><li><strong>Lithium </strong>— raised serum lithium levels and lithium toxicity has been reported. In rare cases lithium has been associated with QT prolongation which may be exacerbated by hypokalaemia of loop diuretics. Advise the person to be aware of (and report) symptoms of lithium toxicity. Monitor lithium levels carefully and adjust the dosage where necessary. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/bipolar-disorder/\">Bipolar disorder</a>.</li><li><strong>Muscle relaxants</strong> — enhanced hypotensive effect with baclofen or tizanidine. Increased effect of curare-like muscle relaxants.</li><li><strong>Nitrates</strong> — enhanced hypotensive effect.</li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— can exacerbate heart failure and increase the risk of hospitalization. Concurrent use need not be avoided but the effects should be monitored and the diuretic dose adjusted as necessary. People at greatest risk are likely to be the elderly with cirrhosis, and/or chronic kidney disease.</li><li><strong>Oestrogens</strong> — diuretic effect antagonized.</li><li><strong>Other diuretics</strong> — risk of profound diuresis and increased risk of electrolyte disturbance. Contraindicated with potassium-sparing diuretics (such as amiloride and spironolactone) due to increased risk of hyperkalaemia.</li><li><strong>Phenobarbital</strong> — concurrent use is not recommended.</li><li><strong>Phenytoin </strong>— the diuretic effects of furosemide can be reduced by as much as 50% by phenytoin. If concurrent use is unavoidable, monitor the diuretic effects of furosemide.</li><li><strong>Potassium salts</strong> — concurrent use is not recommended.</li><li><strong>Progestogens (drosperione)</strong> —increased risk of hyperkalaemia.</li><li><strong>Prostaglandins</strong> — enhanced hypotensive effect with alprostadil.</li><li><strong>Proton pump inhibitors</strong> — hypomagnesaemia can develop after more than one year of concurrent use so consider monitoring magnesium concentrations before, annually, and in response to symptoms of hypomagnesaemia (muscle twitching or cramps, tremors, vomiting, tiredness, or loss of appetite).</li><li><strong>Renin inhibitors</strong> — aliskiren reduces plasma concentration of furosemide.</li><li><strong>Rifampicin</strong> — concurrent use is not recommended.</li><li><strong>Risperidone</strong> — caution with concurrent use of furosemide due to higher risk of mortality.</li><li><strong>Salbutamoland related bronchodilators</strong> — beta2-agonists can cause hypokalaemia. Monitoring of potassium is advised in people with severe asthma because of the probability of multiple potassium-depleting drugs being used. Monitor depending on the severity of the person's condition and the number of potassium-depleting drugs used.</li><li><strong>Salicylates </strong>— effects may be potentiated by furosemide. Salicylic toxicity may be increased by furosemide.</li><li><strong>Theophylline</strong>— enhanced hypotensive effect. Furosemide may increase, decrease, or have no effect on serum theophylline levels. Consider measuring serum theophylline levels and adjust the dose where appropriate. There is a risk of hypokalaemia, so consider monitoring potassium levels in concurrent use.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Preston, 2015</a>]</p><!-- end field ec1c318c-f9d8-474f-976e-0d19d9ea1871 --><!-- end item d1f527c0-e417-4066-bcc3-3c548b7fb98f -->","subChapters":[]},{"id":"3ccc77a0-1e87-5e40-9643-7247356c4086","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 686d7ed0-0e2e-47f2-bdf9-e35f078a2a7b --><h3>Contraindications and cautions of loop diuretics</h3><!-- end field 686d7ed0-0e2e-47f2-bdf9-e35f078a2a7b -->","summary":"","htmlStringContent":"<!-- begin item 51930570-f1fd-41c1-9171-7297f73ac5a2 --><!-- begin field ee350498-228b-4b52-bbb1-1d58b1f8a293 --><ul><li><strong>Do not prescribe loop diuretics to people with:</strong><ul><li>Hypovolaemia and dehydration (with or without accompanying hypotension).</li><li>Severe hypokalaemia or severe hyponatraemia.</li><li>Anuria, acute kidney injury or chronic kidney disease due to nephrotoxic or hepatotoxic drugs, or associated with hepatic coma.</li><li>Chronic kidney disease (CKD) with a creatinine clearance below 30 mL/min/1.73 m<sup>2</sup>.</li><li>Addison's disease.</li><li>Liver cirrhosis associated with comatose and pre-comatose state.</li><li>Porphyria.</li><li>Cardiac arrhythmias (contraindication for torasemide).</li></ul></li><li><strong>Use loop diuretics with caution (and consider the need for dose reduction) in:</strong><ul><li>Older people — they are particularly susceptible to adverse effects. Monitor serum sodium and potassium levels.</li><li>People at risk from significant hypotension.</li><li>People with:<ul><li>Hypovolaemia.</li><li>Electrolyte disturbances, particularly hypokalaemia and hyponatraemia.</li><li>Difficulty with micturition including prostatic hypertrophy — increased risk of urinary retention. Closely monitor people with partial occlusion of the urinary tract.</li><li>Diabetes mellitus — latent diabetes may become overt, and insulin requirements in people with established diabetes may increase.</li><li>Gout — furosemide may raise uric acid levels and precipitate gout.</li><li>Hepatorenal syndrome.</li><li>Impaired hepatic function (during long-term therapy, especially at high doses).</li><li>Chronic kidney disease — frequent monitoring of serum potassium is advised.</li><li>Adrenal disease.</li><li>Hypoproteinaemia (for example nephrotic syndrome) — effect of furosemide may be impaired and the risk of ototoxicity increased. Cautious dose titration is required.</li><li>Acute hypercalcaemia.</li></ul></li></ul></li><li><strong>Consider the possibility of <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-diuretics/#key-drug-interactions\">drug interactions</a> with other medications.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field ee350498-228b-4b52-bbb1-1d58b1f8a293 --><!-- end item 51930570-f1fd-41c1-9171-7297f73ac5a2 -->","subChapters":[]},{"id":"12af02de-be0c-5802-9925-9303ac43cd15","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 78440987-f3ed-4512-9bbb-967a6bdf088f --><h3>Adverse effects of loop diuretics</h3><!-- end field 78440987-f3ed-4512-9bbb-967a6bdf088f -->","summary":"","htmlStringContent":"<!-- begin item a421f3e8-8e65-49e6-a5d3-cfa314e1c953 --><!-- begin field a9a72b47-5a61-4e57-b0a2-5fe6c0a94a1c --><ul><li><strong>Adverse effects of loop diuretics include:</strong><ul><li>Mild gastrointestinal disturbances, pancreatitis, and hepatic encephalopathy.</li><li>Hyperglycaemia.</li><li>Acute urinary retention.</li><li>Water and electrolyte imbalance — including hyponatraemia, hypochloraemia, hypokalaemia, hypomagnesaemia, and hypocalcaemia. Symptoms of electrolyte imbalance depend on the type of disturbance and include:<ul><li>Sodium deficiency — confusion, muscle cramps, muscle weakness, loss of appetite, dizziness, drowsiness, and vomiting.</li><li>Potassium deficiency — neuromuscular symptoms (muscular weakness and paralysis), intestinal symptoms (including vomiting and constipation), renal symptoms (polyuria), and cardiac symptoms (including palpitations). Severe potassium depletion can result in paralytic ileus, confusion, and coma.</li><li>Magnesium and calcium deficiency — tetany and heart rhythm disturbances (very rare).</li></ul></li><li>Hypotension, hypovolaemia, dehydration, and venous thromboembolism — these effects are more likely in older people. They may cause impaired concentration, light headedness, muscle pains, sensation of pressure in the head, headache, tinnitus, hearing loss, dizziness, drowsiness, weakness, gynaecomastia, disorders of vision, and dry mouth. Thrombosis is caused by haemoconcentration as a result of severe fluid depletion.</li><li>Metabolic alkalosis — the risk increases with higher doses.</li><li>Hyperuricaemia.</li><li>Blood disorders (bone marrow suppression, thrombocytopenia, and leucopenia).</li><li>Visual disturbances, tinnitus, and deafness.</li><li>Hypersensitivity reactions.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field a9a72b47-5a61-4e57-b0a2-5fe6c0a94a1c --><!-- end item a421f3e8-8e65-49e6-a5d3-cfa314e1c953 -->","subChapters":[]},{"id":"b7dd9e70-bbbe-53ff-b766-ad1ee55e3447","slug":"managing-abnormal-results","fullItemName":"Managing abnormal results","depth":3,"htmlHeader":"<!-- begin field 005b453a-f9e1-4fb6-97b1-e6fe876cf3d5 --><h3>Managing abnormal results with loop diuretics</h3><!-- end field 005b453a-f9e1-4fb6-97b1-e6fe876cf3d5 -->","summary":"","htmlStringContent":"<!-- begin item 8274a189-3fbb-460f-b73a-f534e315159d --><!-- begin field 4423cf33-f373-4161-8f32-b5a8d4e337d2 --><ul><li><strong>Review the serum creatinine level and estimated glomerular filtration rate (eGFR):</strong><ul><li>If the serum creatinine level increases by more than 20% or the eGFR falls more than 15%, re-measure renal function within 2 weeks.</li><li>An increase in creatinine of 30–50% (or to greater than 200 micromol/L) or an eGFR rate less than 30 mL/min/1.73 m<sup>2</sup> should prompt clinical review of volume status and dose reduction or withdrawal of diuretics (if the person is hypovolaemic). Re-measure renal function within 1 week.</li><li>If there is an increase in creatinine of more than 50% or to greater than 256 micromol/L (eGFR approximately 20–25 mL/min/1.73 m<sup>2</sup>), assess volume status, check blood pressure, review other renal function tests including electrolytes and proteinuria, and review other medication for nephrotoxic agents. If the person is hypovolaemic, stop the diuretic; otherwise, manage accordingly. If there is any uncertainty, seek specialist advice urgently.</li></ul></li><li><strong>Review the serum potassium level:</strong><ul><li>Consider whether the person is at high risk of cardiac arrhythmias with even mild hypokalaemia. People at higher risk include:<ul><li>Elderly people.</li><li>Those taking digoxin or drugs that prolong the QT interval (such as amiodarone).</li><li>Those with paroxysmal arrhythmias, unstable angina, or chronic liver disease.</li></ul></li><li>If the potassium level decreases to less than 3 mmol/L (or 4 mmol/L in high-risk people), review the diuretic treatment dose or consider stopping it.</li><li>If the potassium concentration decreases to less than 2.5 mmol/L (or 3.5 mmol/L in high-risk people), seek specialist advice urgently.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">London and South East Medicines Information Service et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>]</p><!-- end field 4423cf33-f373-4161-8f32-b5a8d4e337d2 --><!-- end item 8274a189-3fbb-460f-b73a-f534e315159d -->","subChapters":[]},{"id":"e4347b15-4702-51d4-ae28-5a3b6132dff7","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field b95ae656-df76-4c95-beff-356392345754 --><h3>Dose and titration of loop diuretics</h3><!-- end field b95ae656-df76-4c95-beff-356392345754 -->","summary":"","htmlStringContent":"<!-- begin item c3105168-0dab-4380-8775-f7557f27fbbf --><!-- begin field 96cf31df-9bae-4bd7-9134-0635eb55b887 --><ul><li><strong>Measure renal function, serum electrolytes and blood pressure before starting loop diuretic treatment and start with a low dose.</strong> Suitable starting doses are shown in Table 5.</li><li><strong>Recheck renal function, serum electrolytes and blood pressure 1–2 weeks after starting treatment.</strong><ul><li>Earlier monitoring (after 5–7 days) may be required for people:<ul><li>With existing chronic kidney disease stage 3 or higher.</li><li>Aged 60 years or over.</li><li>With relevant comorbidities such as diabetes mellitus or peripheral arterial disease.</li><li>Taking a combination of a diuretic plus an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-II receptor antagonist (AIIRA), or an aldosterone antagonist.</li></ul></li><li>For information on interpreting results, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-diuretics/#managing-abnormal-results\">Managing abnormal results</a>.</li></ul></li><li><strong>Titrate the dose of loop diuretic up or down according to symptoms and signs of fluid overload; use the lowest possible dose to control symptoms.</strong><ul><li>Excessive diuresis may cause postural hypotension, dehydration, acute kidney injury, and electrolyte imbalances. If the person shows evidence of symptomatic hypotension, dizziness, light headedness, or confusion), consider reducing the dose of diuretic, or reducing the dose of any concomitant drugs known to reduce blood pressure, or seeking expert advice.</li><li>The dose is usually given once a day, in the morning, but it can be given twice a day (morning and lunchtime) for additional diuresis. People can be advised that they can adjust the timing of doses to suit their social needs.</li><li>For people with heart failure and preserved ejection fraction the maximum initial dose is up to 80 mg furosemide.</li><li>Provide education to the person and their carer regarding how to adjust the dose according to changes in weight, avoiding excessive fluid intake and avoiding dehydration (thirst, dizziness, and fatigue). For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">Self-care advice</a>.<ul><li>Advise the person that if they develop diarrhoea and vomiting while taking, a diuretic, they should maintain their fluid intake and stop the diuretic for 1–2 days until they recover. Stopping treatment for a short time is thought to avoid dehydration, hypotension and acute kidney injury, and should not cause a sudden deterioration in heart failure. If symptoms persist beyond 2 days they should see a GP and have their bloods checked. For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">Self-care advice</a>.</li></ul></li></ul></li><li><strong>Review the loop diuretic dose and adjust as necessary after restoration of dry body weight (removal of most or all the person's excess fluid) and subsequent treatment for heart failure has been introduced,</strong> to reduce the risk of dehydration, acute kidney injury, and electrolyte disturbances.</li><li><strong>Check renal function, serum electrolytes and blood pressure 1–2 weeks after each dose increase.</strong><ul><li>Earlier monitoring (after 5–7 days) may be required for people:<ul><li>With existing chronic kidney disease stage 3 or higher.</li><li>Aged 60 years or over.</li><li>With relevant comorbidities such as diabetes mellitus, or peripheral arterial disease,</li><li>Taking a combination of a diuretic plus an ACE-inhibitor, an AIIRA, or an aldosterone antagonist.</li></ul></li></ul></li><li>Once treatment is stable, measure renal function and serum electrolytes at least once every 6 months.</li></ul><p><strong>Table 5.</strong> Recommended loop diuretic doses for people with heart failure.</p><table data-table-id=\"85749397-fd5a-4ab2-bb29-acce014ecdce\"><thead><tr><th colspan=\"1\" scope=\"col\">Diuretic</th><th colspan=\"1\" scope=\"col\">Daily starting dose</th><th colspan=\"1\" scope=\"col\">Usual daily dose</th></tr></thead><tbody><tr><td colspan=\"1\">Bumetanide</td><td colspan=\"1\">0.5 mg in the elderly–1.0 mg</td><td colspan=\"1\">1–5 mg</td></tr><tr><td colspan=\"1\">Furosemide</td><td colspan=\"1\">20–40 mg</td><td colspan=\"1\">20–120 mg</td></tr><tr><td colspan=\"1\">Torasemide</td><td colspan=\"1\">5-10 mg</td><td colspan=\"1\">10–20 mg</td></tr><tr><td colspan=\"3\"><p><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p></td></tr></tbody></table><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Hippisley-Cox et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">London and South East Medicines Information Service et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Yancy et al, 2013</a>]</p><!-- end field 96cf31df-9bae-4bd7-9134-0635eb55b887 --><!-- end item c3105168-0dab-4380-8775-f7557f27fbbf -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}